抗真菌薬市場 - 世界の産業規模、シェア、動向、機会、予測：薬剤クラス別、適応症別、感染タイプ別、投与経路別、エンドユーザー別、流通チャネル別、地域別、競合別、2020年～2030年

世界の抗真菌薬市場は、2024年に124億7,000万米ドルと評価され、2030年までのCAGRは4.33%で、予測期間中に目覚ましい成長を遂げると予測されています。

真菌感染症の治療には抗真菌薬が一般的に処方されます。これらの薬剤は、経口投与、局所投与、点滴による静脈内投与が可能です。イースト菌感染症、白癬、爪や皮膚の病気などの真菌感染症は、土壌、空気、皮膚に存在する真菌によって引き起こされる可能性があります。また、真菌の胞子を吸い込むと呼吸器系の問題につながることもあります。そのため、免疫力が低下している人は真菌感染症にかかりやすく、抗真菌薬の使用が必要となります。これらの薬のほとんどは医師の処方箋が必要であるが、一部は市販されています。

抗真菌薬には大きく分けて局所性と全身性の2種類があります。治療する症状によって、局所性抗真菌薬は一般的に局所または膣内に塗布され、全身性抗真菌薬は経口または静脈内に投与されます。全身投与薬の例としては、イトラコナゾール、フルコナゾール、ケトコナゾール、ボリコナゾール、ポサコナゾール、イサブコナゾールなどがあります。抗真菌薬には、真菌細胞を直接死滅させる方法と、真菌細胞の増殖や開発を阻害する方法の2つがあります。さらに抗真菌薬は、真菌細胞には必須だがヒト細胞にはない構造や機能を標的とすることで、ヒト細胞を傷つけることなく真菌感染と闘うことができます。真菌の細胞膜と細胞壁は、真菌細胞を取り囲み保護しているため、しばしば標的となる成分です。これらの構造のいずれかが損なわれると、真菌細胞は破裂して死滅します。

主要市場促進要因

真菌感染症の有病率の上昇

主な市場課題

健康への悪影響

主な市場動向

研究開発数の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の抗真菌薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（アゾール、エキノキャンジン、ポリエン、アリルアミン、その他）
  • 適応症別（カンジダ症、アスペルギルス症、ムコール症、皮膚糸状菌症、その他）
  • 感染タイプ別（表在性真菌感染症、全身性真菌感染症）
  • 投与経路別（局所、経口、非経口、その他）
  • エンドユーザー別（在宅ケア、病院、診療所、その他）
  • 流通チャネル別（小売薬局、病院薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の抗真菌薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の抗真菌薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の抗真菌薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の抗真菌薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの抗真菌薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の抗真菌薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Abbott Laboratories Inc.
• Astellas Pharma Inc.
• Bayer AG
• GSK plc
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Mycovia Pharmaceuticals, Inc.
• Apex Laboratories Pvt. Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Anti-Fungal Drugs Market was valued at USD 12.47 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.33% through 2030. Antifungal medications are commonly prescribed to treat fungal infections. These medications can be administered orally, topically, or intravenously via an IV drip. Fungal infections such as yeast infections, ringworm, nail and skin diseases can be caused by fungi present in the soil, air, and skin. Inhaling fungal spores may also lead to respiratory issues. Therefore, individuals with weakened immune systems are more susceptible to fungal infections, necessitating the use of antifungal medication. Most of these medications require a doctor's prescription, although a few are available over the counter.

There are two main categories of antifungal drugs: local and systemic. Depending on the specific condition being treated, local antifungals are commonly applied topically or vaginally, while systemic antifungals are administered orally or intravenously. Examples of systemically administered medicines include itraconazole, fluconazole, ketoconazole, voriconazole, posaconazole, and isavuconazole. Antifungal medications can function in one of two ways: they can directly kill fungal cells or inhibit their growth and development. Moreover, antifungal medications work by targeting structures or functions that are essential in fungal cells but not in human cells, allowing them to combat fungal infections without harming human cells. The fungal cell membrane and cell wall are frequently targeted components, as they surround and protect the fungal cell. Compromising either of these structures can cause the fungal cell to burst open and die.

Key Market Drivers

Rising Prevalence of Fungal Infections

The increasing prevalence of fungal infections is a key driver for the revenue growth in the market. Research indicates that fungal pathogens are responsible for approximately 13 million infections and 1.5 million deaths worldwide each year. Antifungal medications are also administered orally. On March 30, 2023, GSK plc and SCYNEXIS, Inc. announced an exclusive license agreement for Brexafemme, a first-in-class antifungal approved by the U.S. Food and Drug Administration (FDA) for the treatment of Vulvovaginal Candidiasis (VVC) and the reduction of the incidence of recurrent VVC (RVVC). This exclusive licensing deal grants GSK the sole right to commercialize Brexafemme for VVC and RVVC while continuing the development of ibrexafungerp, which is currently in phase III clinical trials for the possible treatment of Invasive Candidiasis (IC), a potentially fatal fungal infection.

The prevalence of fungal infections has been on the rise in recent years, prompting concerns within the healthcare industry. Contributing factors to this alarming trend include increasing global temperatures, the prevalence of chronic illnesses, and compromised immune systems. Hospital-acquired fungal infections, or nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, according to the Centers for Disease Control and Prevention (CDC).

Key Market Challenges

Adverse Health Effects

There are several disadvantages associated with antifungal drugs. One key factor is that individuals with weakened immune systems, such as those with acquired immunodeficiency syndrome (AIDS), lupus, cancer, and other conditions, are more susceptible to dangerous fungal infections known as opportunistic infections. This vulnerability poses a challenge to the revenue growth of the antifungal drug market.

Furthermore, the type of medicine, dosage strength, and the specific fungus being treated can all influence the outcome of the medication. Common side effects may include pain in the abdomen, unsettled stomach, diarrhea, and itchy, scorching, or rashy skin. These symptoms can also have a negative impact on the revenue growth of the market.

In addition to these challenges, antifungal medication can produce major side effects, including liver damage such as jaundice, anaphylaxis, and other severe allergic responses. Blisters and peeling skin are also symptoms of severe allergic skin reactions that can occur as a result of using antifungal drugs. Considering these factors, it becomes evident that while antifungal drugs are necessary for treating fungal infections, they do come with significant drawbacks that need to be taken into account.

Key Market Trends

Increase In the Number of Research and Development Activities

The increase in the number of research and development (R&D) activities in the field of antifungal drugs is expected to significantly boost the demand for these medications. Antifungal drugs are critical for treating a wide range of fungal infections, from superficial conditions like athlete's foot to life-threatening systemic infections. Increasing R&D investments lead to the discovery of new antifungal compounds and formulations. These innovations are likely to result in the development of more effective drugs with improved mechanisms of action, enhancing the arsenal of treatment options available. R&D efforts are dedicated to understanding and combating antifungal resistance. Researchers are working to identify the mechanisms behind resistance and develop strategies to overcome it. This will ensure the continued effectiveness of antifungal drugs, driving their demand. Research in the field of fungal biology is uncovering specific molecular targets within fungal cells that can be exploited for drug development. Targeted therapies can enhance drug efficacy and reduce side effects, making antifungal drugs more appealing to healthcare providers and patients.

Key Market Players

• Abbott Laboratories Inc.
• Astellas Pharma Inc.
• Bayer AG
• GSK plc
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Mycovia Pharmaceuticals, Inc.
• Apex Laboratories Pvt. Ltd.

Report Scope:

In this report, the Global Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Fungal Drugs Market, By Drug Class:

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others

Anti-Fungal Drugs Market, By Indication:

• Candidiasis
• Aspergillosis
• Mucormycosis
• Dermatophytosis
• Others

Anti-Fungal Drugs Market, By Infection Type:

• Superficial Fungal Infection
• Systemic Fungal Infection

Anti-Fungal Drugs Market, By Route of Administration:

• Topical
• Oral
• Parenteral
• Others

Anti-Fungal Drugs Market, By End User:

• Homecare
• Hospitals
• Clinics
• Others

Anti-Fungal Drugs Market, By Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Anti-Fungal Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Fungal Drugs Market.

Available Customizations:

Global Anti-Fungal Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Fungal Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
  • 5.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
  • 5.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
  • 5.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
  • 5.2.5. By End User (Homecare, Hospitals, Clinics, Others)
  • 5.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
  • 5.2.7. By Region
  • 5.2.8. By Company (2024)
• 5.3. Market Map

6. North America Anti-Fungal Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Indication
  • 6.2.3. By Infection Type
  • 6.2.4. By Route Of Administration
  • 6.2.5. By End User
  • 6.2.6. By Distribution Channel
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Fungal Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Infection Type
      • 6.3.1.2.4. By Route Of Administration
      • 6.3.1.2.5. By End User
      • 6.3.1.2.6. By Distribution Channel
  • 6.3.2. Canada Anti-Fungal Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Infection Type
      • 6.3.2.2.4. By Route Of Administration
      • 6.3.2.2.5. By End User
      • 6.3.2.2.6. By Distribution Channel
  • 6.3.3. Mexico Anti-Fungal Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Infection Type
      • 6.3.3.2.4. By Route Of Administration
      • 6.3.3.2.5. By End User
      • 6.3.3.2.6. By Distribution Channel

7. Europe Anti-Fungal Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Indication
  • 7.2.3. By Infection Type
  • 7.2.4. By Route Of Administration
  • 7.2.5. By End User
  • 7.2.6. By Distribution Channel
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Fungal Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Infection Type
      • 7.3.1.2.4. By Route Of Administration
      • 7.3.1.2.5. By End User
      • 7.3.1.2.6. By Distribution Channel
  • 7.3.2. United Kingdom Anti-Fungal Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Infection Type
      • 7.3.2.2.4. By Route Of Administration
      • 7.3.2.2.5. By End User
      • 7.3.2.2.6. By Distribution Channel
  • 7.3.3. Italy Anti-Fungal Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Infection Type
      • 7.3.3.2.4. By Route Of Administration
      • 7.3.3.2.5. By End User
      • 7.3.3.2.6. By Distribution Channel
  • 7.3.4. France Anti-Fungal Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Infection Type
      • 7.3.4.2.4. By Route Of Administration
      • 7.3.4.2.5. By End User
      • 7.3.4.2.6. By Distribution Channel
  • 7.3.5. Spain Anti-Fungal Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Infection Type
      • 7.3.5.2.4. By Route Of Administration
      • 7.3.5.2.5. By End User
      • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Anti-Fungal Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Indication
  • 8.2.3. By Infection Type
  • 8.2.4. By Route Of Administration
  • 8.2.5. By End User
  • 8.2.6. By Distribution Channel
  • 8.2.7. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Anti-Fungal Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Infection Type
      • 8.3.1.2.4. By Route Of Administration
      • 8.3.1.2.5. By End User
      • 8.3.1.2.6. By Distribution Channel
  • 8.3.2. India Anti-Fungal Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Infection Type
      • 8.3.2.2.4. By Route Of Administration
      • 8.3.2.2.5. By End User
      • 8.3.2.2.6. By Distribution Channel
  • 8.3.3. Japan Anti-Fungal Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Infection Type
      • 8.3.3.2.4. By Route Of Administration
      • 8.3.3.2.5. By End User
      • 8.3.3.2.6. By Distribution Channel
  • 8.3.4. South Korea Anti-Fungal Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Infection Type
      • 8.3.4.2.4. By Route Of Administration
      • 8.3.4.2.5. By End User
      • 8.3.4.2.6. By Distribution Channel
  • 8.3.5. Australia Anti-Fungal Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Infection Type
      • 8.3.5.2.4. By Route Of Administration
      • 8.3.5.2.5. By End User
      • 8.3.5.2.6. By Distribution Channel

9. South America Anti-Fungal Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Indication
  • 9.2.3. By Infection Type
  • 9.2.4. By Route Of Administration
  • 9.2.5. By End User
  • 9.2.6. By Distribution Channel
  • 9.2.7. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Anti-Fungal Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Infection Type
      • 9.3.1.2.4. By Route Of Administration
      • 9.3.1.2.5. By End User
      • 9.3.1.2.6. By Distribution Channel
  • 9.3.2. Argentina Anti-Fungal Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Infection Type
      • 9.3.2.2.4. By Route Of Administration
      • 9.3.2.2.5. By End User
      • 9.3.2.2.6. By Distribution Channel
  • 9.3.3. Colombia Anti-Fungal Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Infection Type
      • 9.3.3.2.4. By Route Of Administration
      • 9.3.3.2.5. By End User
      • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Anti-Fungal Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Indication
  • 10.2.3. By Infection Type
  • 10.2.4. By Route Of Administration
  • 10.2.5. By End User
  • 10.2.6. By Distribution Channel
  • 10.2.7. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Anti-Fungal Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Infection Type
      • 10.3.1.2.4. By Route Of Administration
      • 10.3.1.2.5. By End User
      • 10.3.1.2.6. By Distribution Channel
  • 10.3.2. Saudi Arabia Anti-Fungal Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Infection Type
      • 10.3.2.2.4. By Route Of Administration
      • 10.3.2.2.5. By End User
      • 10.3.2.2.6. By Distribution Channel
  • 10.3.3. UAE Anti-Fungal Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Infection Type
      • 10.3.3.2.4. By Route Of Administration
      • 10.3.3.2.5. By End User
      • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Anti-Fungal Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Astellas Pharma Inc.
• 15.3. Bayer AG
• 15.4. GSK plc
• 15.5. Glenmark Pharmaceuticals Limited
• 15.6. Merck & Co. Inc.
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Mycovia Pharmaceuticals, Inc.
• 15.10. Apex Laboratories Pvt. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer